Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
Last trade$8.71
Day change-$0.61 (-6.55%)
Day range$8.64 – $9.62
Volume135,145
Market cap$155M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$154.73M
Price / earnings
—
Price / book
-1.17×
Price / sales
3.43×
EV / sales
2.39×
EV / EBITDA
-0.99×
Profitability
Earnings per share
-$9.35
Return on assets
-87.9%
Return on equity
117.15%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-0×
Current ratio
2.94×
Quick ratio
2.94×
Cash ratio
0.86×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$129.76M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for STRO, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$9.1M
$9.84M
$14.52M
$11.65M
$9.69M
$63.75M
$17.4M
$14.81M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$9.1M
$9.84M
$14.52M
$11.65M
$9.69M
$63.75M
$17.4M
$14.81M
Selling, general and administrative
$7.54M
$7.83M
$7.58M
$8.66M
$8.74M
$10.34M
$13.27M
$9.03M
Research and development
$23.5M
$31.7M
$36.55M
$36.64M
$39.85M
$38.33M
$51.6M
$71.04M
Total operating expenses
$31.05M
$39.73M
$44.18M
$49.7M
$58.15M
$67.09M
$85.91M
$80.07M
Operating income
-$21.96M
-$29.89M
-$29.66M
-$38.05M
-$48.46M
-$3.35M
-$68.51M
-$65.26M
Interest expense
-$10.15M
-$9.86M
-$9.47M
-$9.55M
-$9.67M
-$9.65M
-$9.34M
-$8.69M
Income before taxes
-$31.49M
-$38.53M
-$38.5M
-$46.84M
-$56.86M
-$11.52M
-$75.96M
-$70.09M
Income taxes
$0
$1K
-$15K
-$82K
$0
-$18K
$7K
$2.36M
Net income
-$31.49M
-$38.53M
-$38.48M
-$46.76M
-$56.86M
-$11.5M
-$75.97M
-$72.44M
Net income attributable to common shareholders
-$31.49M
-$38.53M
-$38.48M
-$46.76M
-$56.86M
-$11.5M
-$75.97M
-$72.44M
EBITDA
-$20.7M
-$28.43M
-$28.34M
-$32.03M
-$37M
$16.98M
-$45.57M
-$63.39M
Basic earnings per share
-$1.90
-$2.33
-$2.94
-$5.45
-$6.66
-$1.35
-$9.08
-$8.55
Diluted earnings per share
-$1.90
-$2.33
-$2.94
-$5.45
-$6.66
-$1.35
-$9.08
-$8.55
Recent news
Company coverage with links to the original publishers.
Upstream Bio (UPB) reported a quarterly loss of $0.75 per share, missing consensus estimates of $0.67, and posted revenues of $0.4 million, down 41% year-over-year and missing estimates by 49%. The stock has declined 86.8% year-to-date, significantly underperforming the S&P 500's 10.3% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions.
Sutro Biopharma, a clinical-stage oncology company specializing in antibody drug conjugates (ADCs), announced that management will participate in multiple investor conferences from November through December 2026, including events hosted by Stifel, Truist Securities, UBS, Jefferies, and Piper Sandler. Live webcasts and archived replays will be available on the company's investor relations website.
Axsome Therapeutics (AXSM) reported a quarterly loss of $0.25 per share, beating consensus estimates of $0.69 loss by 63.77%, with revenues of $259.69 million exceeding expectations by 5.37%. However, the stock has underperformed the market, declining 20.9% year-to-date versus the S&P 500's 10.7% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
Sutro Biopharma announced promising preclinical data for its ADC pipeline at AACR 2026, with STRO-004 demonstrating robust antitumor activity across multiple solid tumor models and improved efficacy versus benchmark ADCs. The company also presented data for STRO-006 and STRO-227, with IND submissions planned for 2026. Partner Astellas presented results from ASP2998, a TROP2-targeted immunostimulatory ADC that entered clinical trials earlier in 2026.
Sutro Biopharma announced the pricing of an underwritten offering of 7,868,383 shares at $13.98 per share, generating approximately $110 million in gross proceeds. The offering includes participation from multiple investors and is expected to close on February 11, 2026. Proceeds will be used for research, clinical development, manufacturing, and general corporate purposes.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.